Division of Gastroenterology, Department of Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok 10330, Thailand.
Program in Clinical Sciences (International Program), Graduate Affairs, Faculty of Medicine, Chulalongkorn University, Bangkok 10330, Thailand.
Br J Radiol. 2024 Oct 1;97(1162):1671-1682. doi: 10.1093/bjr/tqae140.
With ultrasound sensitivity limited in hepatocellular carcinoma (HCC) surveillance and few prospective studies on non-contrast abbreviated MRI (NC-AMRI), this study aimed to assess its diagnostic performance in detecting HCC.
This prospective study involved cirrhotic patients with contrast-enhanced MRI (CE-MRI) Liver Imaging Reporting and Data System (LI-RADS) LR-3 and LR-4 observations detected during HCC surveillance. Patients underwent average 3 complete CE-MRI rounds at 3-6 months interval, with approximately 12-month follow-up. NC-AMRI included diffusion-weighted (DWI), T2-weighted imaging (T2WI), and T1-weighted imaging (T1WI). NC-AMRI protocol images were analysed for diagnostic performance, with subgroup analyses. CE-MRI and NC-AMRI images were independently reviewed by 2 experienced radiologists, with inter-reader agreement assessed with Kappa coefficient. The reference standard was the American Association for the Study of Liver Diseases-defined presence of arterial hypervascularity and washout during the portal-venous or delayed phases on CE-MRI.
In 166 CE-MRI follow-ups of 63 patients (median age: 63 years; 60.3% male, 39.7% female), 12 patients developed HCC, with average size of 19.6 mm. The NC-AMRI (DWI + T2WI + T1WI) showed 91.7% sensitivity (95%CI, 61.5-99.8) and 91.6% specificity (95%CI, 86.0-95.4), area under receiver operating characteristic 0.92 (95%CI, 0.83-1.00). Across different Body Mass Index categories, lesion size, Child-Turcotte-Pugh classes, Albumin-Bilirubin (ALBI) grades, and Model for End-Stage Liver Disease classes, sensitivity remained consistent. However, specificity differed significantly between ALBI grade 1 and 2 (86.7% vs. 98.4%, P = .010), and between viral and non-viral cirrhosis (93.8% vs. 80.8%, P = .010).
NC-AMRI proved clinically feasible, and exhibits high diagnostic performance in HCC detection.
This study highlights efficacy of NC-AMRI in detecting HCC among cirrhotic patients with LR-3 and LR-4 observations, representing significant progress in HCC surveillance.
由于超声在肝细胞癌(HCC)监测中的灵敏度有限,且关于非对比性简化磁共振成像(NC-AMRI)的前瞻性研究较少,本研究旨在评估其在检测 HCC 中的诊断性能。
本前瞻性研究纳入了 HCC 监测期间经增强磁共振成像(CE-MRI)肝脏成像报告和数据系统(LI-RADS)LR-3 和 LR-4 观察到的肝硬化患者。患者接受了平均 3 轮完整的 CE-MRI 检查,每 3-6 个月一次,随访时间约为 12 个月。NC-AMRI 包括弥散加权成像(DWI)、T2 加权成像(T2WI)和 T1 加权成像(T1WI)。分析 NC-AMRI 方案图像的诊断性能,并进行亚组分析。CE-MRI 和 NC-AMRI 图像由 2 名经验丰富的放射科医生独立进行评估,使用 Kappa 系数评估读者间的一致性。参考标准为美国肝病研究协会定义的动脉期高血供和门静脉期或延迟期洗脱在 CE-MRI 上的存在。
在 63 名患者的 166 次 CE-MRI 随访中(中位年龄:63 岁;60.3%为男性,39.7%为女性),12 名患者发生 HCC,平均大小为 19.6mm。NC-AMRI(DWI+T2WI+T1WI)的灵敏度为 91.7%(95%CI,61.5-99.8),特异性为 91.6%(95%CI,86.0-95.4),受试者工作特征曲线下面积为 0.92(95%CI,0.83-1.00)。在不同的体重指数类别、病变大小、Child-Turcotte-Pugh 分级、白蛋白-胆红素(ALBI)分级和终末期肝病模型(MELD)分级中,灵敏度保持一致。然而,特异性在 ALBI 分级 1 和 2 之间差异显著(86.7%比 98.4%,P=0.010),在病毒性和非病毒性肝硬化之间差异显著(93.8%比 80.8%,P=0.010)。
NC-AMRI 在检测肝硬化患者的 HCC 中具有较高的诊断性能,具有较高的诊断性能。
本研究强调了 NC-AMRI 在检测 LR-3 和 LR-4 观察到的肝硬化患者 HCC 中的有效性,这代表了 HCC 监测方面的重要进展。